Dr Reddy's Laboratories EBITDA 2010-2024 | RDY

Dr Reddy's Laboratories EBITDA for the quarter ending June 30, 2024 was $0.261B, a 1.16% increase year-over-year.

  • Dr Reddy's Laboratories 2024 EBITDA was 0.99B, a 16.61% increase from 2023.
  • Dr Reddy's Laboratories 2023 EBITDA was 0.849B, a 55.78% increase from 2022.
  • Dr Reddy's Laboratories 2022 EBITDA was 0.545B, a 12.66% decline from 2021.

EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.

Dr Reddy's Laboratories EBITDA 2010-2024 | RDY

  • Dr Reddy's Laboratories 2024 EBITDA was 0.99B, a 16.61% increase from 2023.
  • Dr Reddy's Laboratories 2023 EBITDA was 0.849B, a 55.78% increase from 2022.
  • Dr Reddy's Laboratories 2022 EBITDA was 0.545B, a 12.66% decline from 2021.

EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
Related Stocks
Company NameMarket
Cap
Teva Pharmaceutical Industries (TEVA)$19.4B
BridgeBio Pharma (BBIO)$5.1B
Bausch Health Cos (BHC)$3.4B
Amphastar Pharmaceuticals (AMPH)$2.4B
Supernus Pharmaceuticals (SUPN)$2B
Taysha Gene Therapies (TSHA)$307M
Personalis (PSNL)$241M
Assembly Biosciences (ASMB)$106M
Sol-Gel Technologies (SLGL)$16M
Evoke Pharma (EVOK)$5M
Teligent (TLGT)$0M